Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates that target serious rare and ocular diseases. It leverages its adeno-associated virus (AAV)-based directed evolution platform to develop products. The company's pipeline of product candidates include ADVM-043 to treat alpha-1 antitrypsin deficiency, which is in Phase I/II clinical trial; and ADVM-053 for hereditary angioedema disease, which is in preclinical stage; as well as ADVM-022 and ADVM-032 for wet age-related macular degeneration disease, which are in preclinical stage. It has collaboration agreement with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets, as well as includes AVA-311 for the treatment of juvenile X-Linked Retinoschisis. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADVM
Previous Symbol
CUSIPN/A
Phone650-272-6269
Debt
Debt-to-Equity RatioN/A
Current Ratio22.08
Quick Ratio22.08
Price-To-Earnings
Trailing P/E Ratio-2.86
Forward P/E Ratio-3.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.85 million
Price / Sales125.40
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.09 per share
Price / Book0.90
Profitability
EPS (Most Recent Fiscal Year)($1.29)
Net Income$-56,140,000.00
Net Margins-3,582.48%
Return on Equity-30.38%
Return on Assets-28.67%
Miscellaneous
Employees78
Outstanding Shares62,870,000
Market Cap$228.84 million
OptionableOptionable
Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions
What is Adverum Biotechnologies' stock symbol?
Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."
How were Adverum Biotechnologies' earnings last quarter?
Adverum Biotechnologies Inc (NASDAQ:ADVM) posted its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.04. The biotechnology company earned $0.83 million during the quarter, compared to the consensus estimate of $0.27 million. Adverum Biotechnologies had a negative return on equity of 30.38% and a negative net margin of 3,582.48%. View Adverum Biotechnologies' Earnings History.
When is Adverum Biotechnologies' next earnings date?
What price target have analysts set for ADVM?
5 analysts have issued 1-year price targets for Adverum Biotechnologies' stock. Their forecasts range from $4.00 to $11.00. On average, they expect Adverum Biotechnologies' stock price to reach $6.8750 in the next year. This suggests a possible upside of 86.3% from the stock's current price. View Analyst Price Targets for Adverum Biotechnologies.
What is the consensus analysts' recommendation for Adverum Biotechnologies?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adverum Biotechnologies.
What are Wall Street analysts saying about Adverum Biotechnologies stock?
Here are some recent quotes from research analysts about Adverum Biotechnologies stock:
- 1. According to Zacks Investment Research, "Adverum Biotechnologies, Inc. is a gene therapy company. The Company discovers and develops novel medicines for patients living with rare diseases. Adverum Biotechnologies Inc, formerly known as Avalanche Biotechnologies Inc., is headquartered in Menlo Park, California. " (11/15/2018)
- 2. Cantor Fitzgerald analysts commented, ". We are downgrading and reducing our 12-month PT to $4 from $12. The new PT is solely based on the ADVM-022 wAMD program, soon to enter P1 testing in 2018. Our changed perspective results from the PR Friday that the company discontinued development of lead asset ADVM-043 for treatment of A1AT deficiency and hit pause on the preclinical HAE program, deciding not to file an IND in 4Q18. Although further clarity on rare disease programs is expected in 1H19, we now see only the wAMD program as a potential driver of value over the next ~12-18 months." (11/4/2018)
- 3. Chardan Capital analysts commented, "We had previously expressed concerns on ADVM-043. In our 9 August 2018 research, we stated [t]hus even if safety signals are reassuring, there may be some question on efficacy in final data." Based on the failure of DTX101, and uncertainty on the liver tropism of AAVrh10, we saw issues with the design of ADMV-043. Further, a serious of previous failures of AAV-based GT for A1AT from other organizations including AGTC (Neutral) suggest this is a difficult indication to treat with GT. We look for better datasets in the remaining Adverum pipeline. The OPTIC phase I trial of ADVM-022, an AAV7m8-based, intravitreal anti- VEGF GT for wet AMD, is due to begin dosing in 4Q18. 2018 research detailed our concerns on this asset." (11/2/2018)
Has Adverum Biotechnologies been receiving favorable news coverage?
News headlines about ADVM stock have trended positive on Wednesday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adverum Biotechnologies earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next few days.
Who are some of Adverum Biotechnologies' key competitors?
Some companies that are related to Adverum Biotechnologies include Solid Biosciences (SLDB), Acorda Therapeutics (ACOR), Gritstone Oncology (GRTS), Cellectis (CLLS), DBV TECHNOLOGIE/S (DBVT), Novavax (NVAX), Twist Bioscience (TWST), Heska (HSKA), Vericel (VCEL), Coherus Biosciences (CHRS), BAVARIAN NORDIC/S (BVNRY), Scholar Rock (SRRK), Avrobio (AVRO), Adaptimmune Therapeutics (ADAP) and NanoString Technologies (NSTG).
Who are Adverum Biotechnologies' key executives?
Adverum Biotechnologies' management team includes the folowing people:
- Dr. Mehdi Gasmi, Pres & Chief Scientific Officer (Age 51)
- Dr. Mitchell H. Finer, Co-Founder & Director (Age 59)
- Dr. Amber Salzman, Consultant (Age 56)
- Ms. Leone D. Patterson, CEO, CFO & Director (Age 55)
- Ms. Katherine Bock, VP of Investor Relations & Corp. Communications
Who are Adverum Biotechnologies' major shareholders?
Adverum Biotechnologies' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.89%), Renaissance Technologies LLC (5.63%), JPMorgan Chase & Co. (4.41%), JPMorgan Chase & Co. (4.40%), Vanguard Group Inc. (3.57%) and Dimensional Fund Advisors LP (2.61%). View Institutional Ownership Trends for Adverum Biotechnologies.
Which institutional investors are selling Adverum Biotechnologies stock?
Which institutional investors are buying Adverum Biotechnologies stock?
ADVM stock was purchased by a variety of institutional investors in the last quarter, including WS Management Lllp, BlackRock Inc., Marshall Wace North America L.P., Primecap Management Co. CA, JPMorgan Chase & Co., JPMorgan Chase & Co., Renaissance Technologies LLC and AQR Capital Management LLC. View Insider Buying and Selling for Adverum Biotechnologies.
How do I buy shares of Adverum Biotechnologies?
Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adverum Biotechnologies' stock price today?
One share of ADVM stock can currently be purchased for approximately $3.69.
How big of a company is Adverum Biotechnologies?
Adverum Biotechnologies has a market capitalization of $228.84 million and generates $1.85 million in revenue each year. The biotechnology company earns $-56,140,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. Adverum Biotechnologies employs 78 workers across the globe.
What is Adverum Biotechnologies' official website?
How can I contact Adverum Biotechnologies?
Adverum Biotechnologies' mailing address is 1035 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-272-6269 or via email at [email protected]
MarketBeat Community Rating for Adverum Biotechnologies (NASDAQ ADVM)
MarketBeat's community ratings are surveys of what our community members think about Adverum Biotechnologies and other stocks. Vote "Outperform" if you believe ADVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
